A phase II, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation

Acute graft-versus-host disease (aGvHD) is a life-threatening complication typically occurring within 100 days after allogeneic hematopoietic cell transplantation (allo-HCT). This hypothesis-generating, phase II, prospective, open-label, randomized study (clinicaltrials gov. Identifier: NCT03339297)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hudspeth, Michelle, Mori, Shahram, Nachbaur, David, Perez-Simon, José Antonio, Stölzel, Friedrich, Riches, Marcie, Wu, Wendy, Zhang, Peixin, Agarwal, Shirali, Yakoub-Agha, Ibrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Bone Marrow Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071105/
https://www.ncbi.nlm.nih.gov/pubmed/36519326
http://dx.doi.org/10.3324/haematol.2022.281471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071105/
https://www.ncbi.nlm.nih.gov/pubmed/36519326
http://dx.doi.org/10.3324/haematol.2022.281471

Ejemplares similares